Structure Therapeutics hires Matthew Lang as COO and General Counsel ahead of Phase 3

Filed April 15, 2026 · Period ending April 15, 2026 · ~1 min read

Key Changes

• medium

  Matthew Lang appointed Chief Operating Officer and General Counsel effective April 15, 2026, consolidating operational and legal leadership as the company prepares to advance obesity drug aleniglipron into Phase 3 trials.

  Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation verify on EDGAR →
• medium

  Lang brings experience guiding Metsera through its up to $10 billion Pfizer acquisition and leading two Myovant drugs through Phase 3 development to global approval and commercialization, relevant experience for Structure's late-stage plans.

  Exhibit 99.1 verify on EDGAR →
• low

  Compensation includes $560,000 base salary, 40% target bonus, stock options for 74,592 ADSs, time-based RSUs for 61,538 ADSs, and performance RSUs for 15,385 ADSs at target with milestones through June 2029.

  Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation verify on EDGAR →